ACM
NRIX icon

AlphaCrest Capital Management’s Nurix Therapeutics NRIX Stock Holding History

AlphaCrest Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9,842
Closed -$285K – 1357
2021
Q4 		$285K Buy
+9,842
New +$298K 0.01% 1268

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

AlphaCrest Capital Management's NRIX Position: Q1 2022 in Review

AlphaCrest Capital Management sold out of Nurix Therapeutics (NRIX) in Q1 2022, closing a stake of 9,842 shares — an estimated $285K sold.

AlphaCrest Capital Management first reported a position in NRIX in Q4 2021 and held it in 1 quarter. The position peaked at $285K in Q4 2021. 117 funds tracked by Wall St. Rank hold NRIX as of Q1 2022.

  • AlphaCrest Capital Management reported no remaining Nurix Therapeutics position as of Q1 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 9,842 Nurix Therapeutics shares in Q1 2022, an estimated $285K.
  • AlphaCrest Capital Management first reported a position in Nurix Therapeutics in Q4 2021 and held it in 1 quarter.
  • AlphaCrest Capital Management's Nurix Therapeutics position peaked at $285K in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2022.

Based on AlphaCrest Capital Management's 13F filing for Q1 2022, filed 12 May 2022.